Canada’s main stock index registered more gains on Thursday, driven by materials stocks tracking higher metals prices. Utilities led gainers on the TSX while energy and industrials led the drop. Investors have been coming to terms with the fact the U.S. Federal Reserve won’t cut rates around June as previously hoped.

Bank of America’s CEO comments to media, coupled with economists polled by Reuters, have shifted the consensus belief that the Fed will wait until September to cut its key interest rate. U.S. markets attempted to recover lost ground, despite being on track for a losing week. Yields in the bond market charged higher after more reports showed the U.S. economy remains stronger than expected.

TSX21,708.44+52.39TSX
TSXV570.89-0.95TSXV
CSE190.79-4.42CSE
DJIA37,775.38+22.07DJIA
NASDAQ15,601.50-81.87NASDAQ
S&P 5005,011.17-11.04S&P 500

The Canadian dollar traded for 72.63 cents compared with 72.46 cents U.S. on Wednesday.

U.S. crude futures traded $0.01 lower at $82.68 a barrel, and the Brent contract lost $0.24 to $87.05 a barrel.

The price of gold was up US$12.44 to US$2,380.41.

In world markets, the Nikkei was up 117.90 points to 38,079.70, the Hang Seng was up 134.03 points to 16,385.87, the FTSE was up 29.06 points to 7,877.05, and the DAX was up 80.79 points to 17,850.81.


The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.


More From The Market Online
Laurion Mineral Exploration Ishkõday gold project

Top-performing mining stock adds three new gold zones

Laurion Mineral Exploration (TSXV:LME), a top-performing junior gold stock, shares assay results from its 2024 drilling program in Ontario.
Negotiating in a meeting room

Hempalta acquires controlling interest in Hemp Carbon Standard

Hempalta (TSXV:HEMP) completes its acquisition of controlling interest in Hemp Carbon Standard equalling 50.1 per cent of shares.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.
Bombardier - Bombardier's Challenger 3500 business jet.

Bombardier reveals NetJets as buyer behind US$6 billion order

Bombardier (TSX:BBD.A) names NetJets as the previously announced anonymous buyer of 12 Challenger 3500 aircraft in December 2023.